ArticleBMC pulmonary medicine2025
Difference in efficacy between pulmonary endarterectomy and balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical research on pulmonary hypertension from a 2025 perspective: a narrative review.Journal of thoracic disease · 2026Review
- Current Perspectives on Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBoth pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA) can be considered for the invasive treatment of chronic thromboembolic pulmonary hypertension (CTEPH). However, the technique applied to treat pulmonary vessels differs between PEA and BPA. While PEA removes lesions with thickened intima and organized thrombus, BPA improves pulmonary arterial flow by dilating stenosis and obstruction without removing the lesions. There have been limited reports on the differential efficacy between PEA and BPA. This study aimed to compare the baseline characteristics and efficacy of both treatments in CTEPH.
methodsBetween November 2001 and May 2019, 55 patients underwent PEA and 77 had only BPA performed. We evaluated clinical parameters before performing PEA and BPA, and on follow-up.
resultsThe patients who underwent BPA were older and had fewer proximal lesions and milder pulmonary hemodynamics compared with those who underwent PEA (mean pulmonary arterial pressure: 34.0 ± 8.6 vs. 43.0 ± 9.9 mm Hg, p < 0.001). Although both groups showed improvement in most of their clinical data, cardiac index was not improved by BPA as opposed to PEA (2.5 ± 0.6 to 2.5 ± 0.6 L/min/m
conclusionsBPA did not change RC time and cardiac index, while PEA reduced RC time and improved cardiac index. The technical approach of removing intra-vascular organized thrombi and thickened intima by PEA could have a more profound impact on pulmonary circulation and cardiac function improvements compared with BPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.